Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2021-12-17 DOI:10.2217/bmt-2021-0006

F. Canino, L. Moscetti, V. Borghi, M. Dominici, F. Piacentini

引用次数: 0

Abstract

The use of drugs that affect the cell cycle represents one of the common strategies for the control of some unrelated pathologies, such as chronic viral HIV infections or cancer. The authors report the case of a patient followed for a hormone receptor-positive (HR+)/HER2 negative (HER2-) advanced breast cancer, treated with hormone therapy and CDK 4/6 inhibitors, and a concomitant HIV infection under antiretroviral treatment. The authors consider the function of the sterile alpha motif and HD domain-containing protein-1 (SAMHD1) enzyme, its implications in the control of viral replication and the correlation between its activity and the mechanism of action of the CDK 4/6 inhibitor palbociclib.

查看原文本刊更多论文

帕博西尼治疗HR+/HER2晚期乳腺癌合并hiv感染1例

使用影响细胞周期的药物是控制一些无关疾病的常见策略之一，如慢性病毒性HIV感染或癌症。作者报告了一例激素受体阳性（HR+）/HER2阴性（HER2-）晚期癌症患者，接受激素治疗和CDK4/6抑制剂治疗，并在抗逆转录病毒治疗下伴有艾滋病毒感染。作者考虑了无菌α基序和HD结构域含蛋白-1（SAMHD1）酶的功能，它在控制病毒复制中的意义，以及它的活性与CDK4/6抑制剂帕博西立布的作用机制之间的相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.